(Q44004407)

28 November 2017

title

Hyperhomocysteinemia and impaired vasomotor function in type 2 diabetes mellitus (English)

1 reference

28 November 2017

1 reference

5

1 reference

28 November 2017

K C B Tan

1

1 reference

28 November 2017

Karmin O

2

1 reference

28 November 2017

W-S Chow

3

1 reference

28 November 2017

V H G Ai

4

1 reference

28 November 2017

K S L Lam

6

1 reference

28 November 2017

publication date

1 May 2002

1 reference

European Journal of Clinical Investigation

28 November 2017

published in

1 reference

28 November 2017

volume

32

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

328-334

1 reference

Homocysteine and coronary atherosclerosis

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Homocysteine: an emergent cardiovascular risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Flow associated or flow mediated dilatation? More than just semantics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.00990.X

10.1046/J.1365-2362.2002.00990.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference